Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.

Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.
Clin Immunol. 2020 Apr 29;:108451
Authors: Takatani A, Koga T, Fujita Y, Fukui S, Endo Y, Shimizu T, Kawakami A
PMID: 32360518 [PubMed - as supplied by publisher]

Source: Clinical Immunology - April 28, 2020 Category: Allergy & Immunology Authors: Takatani A, Koga T, Fujita Y, Fukui S, Endo Y, Shimizu T, Kawakami A Tags: Clin Immunol Source Type: research